Tags

Type your tag names separated by a space and hit enter

[New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
Brain Nerve. 2020 May; 72(5):517-523.BN

Abstract

Multiple sclerosis disease modifying drugs (MS-DMD) currently used in Japan are interferon β-1a, interferon β-1b and gratiramer acetate, fingolimod, dimethyl furmarate, and natalizumab. Ofatumumab and siponimod will be approved probably in 2021. Ofatumumab is an ant-CD20 human monoclonal antibody. A clinical trial revealed that the efficacy of ofatumumab is clearly superior to teriflunomide that has comparable efficacy to dimethyl fumarate. Siponimod, a selective sphingosine-1-phosphate receptor modulator, exhibited mild, but significant efficacy for secondary progressive form of MS. OCH, a synthetic glycolipid agent, is being tested in phase II clinical trials in Japan. What DMD is to select is challenging since MS prognosis varies and is unexpected. Only very few have truly benign course without treatment. Silent progression should be considered especially in cases with those with interferon β-1a, interferon β-1b and gratiramer acetate. Escalation therapy is more widely accepted than initiation of high efficacy therapy in Japan because emphasizing safety. In such strategy three injectables and dimethyl fumarate are regarded as first line therapies. On the other hand, initiation of high efficacy drugs may be reasonable to prevent from disease progression. Even if either is acceptable, early induction of DMD with sufficient efficacy is mandatory for MS treatment.

Authors+Show Affiliations

Department of Neurology, Kansai Medical University Medical Center.

Pub Type(s)

English Abstract
Journal Article

Language

jpn

PubMed ID

32381749

Citation

Kondo, Takayuki. "[New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan]." Brain and Nerve = Shinkei Kenkyu No Shinpo, vol. 72, no. 5, 2020, pp. 517-523.
Kondo T. [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan]. Brain Nerve. 2020;72(5):517-523.
Kondo, T. (2020). [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan]. Brain and Nerve = Shinkei Kenkyu No Shinpo, 72(5), 517-523. https://doi.org/10.11477/mf.1416201555
Kondo T. [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan]. Brain Nerve. 2020;72(5):517-523. PubMed PMID: 32381749.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan]. A1 - Kondo,Takayuki, PY - 2020/5/9/entrez SP - 517 EP - 523 JF - Brain and nerve = Shinkei kenkyu no shinpo JO - Brain Nerve VL - 72 IS - 5 N2 - Multiple sclerosis disease modifying drugs (MS-DMD) currently used in Japan are interferon β-1a, interferon β-1b and gratiramer acetate, fingolimod, dimethyl furmarate, and natalizumab. Ofatumumab and siponimod will be approved probably in 2021. Ofatumumab is an ant-CD20 human monoclonal antibody. A clinical trial revealed that the efficacy of ofatumumab is clearly superior to teriflunomide that has comparable efficacy to dimethyl fumarate. Siponimod, a selective sphingosine-1-phosphate receptor modulator, exhibited mild, but significant efficacy for secondary progressive form of MS. OCH, a synthetic glycolipid agent, is being tested in phase II clinical trials in Japan. What DMD is to select is challenging since MS prognosis varies and is unexpected. Only very few have truly benign course without treatment. Silent progression should be considered especially in cases with those with interferon β-1a, interferon β-1b and gratiramer acetate. Escalation therapy is more widely accepted than initiation of high efficacy therapy in Japan because emphasizing safety. In such strategy three injectables and dimethyl fumarate are regarded as first line therapies. On the other hand, initiation of high efficacy drugs may be reasonable to prevent from disease progression. Even if either is acceptable, early induction of DMD with sufficient efficacy is mandatory for MS treatment. SN - 1881-6096 UR - https://www.unboundmedicine.com/medline/citation/32381749/[New_Arrival_of_Disease_Modifying_Drugs_Initiates_New_Era_in_Multiple_Sclerosis_Treatment_in_Japan] L2 - https://webview.isho.jp/openurl?rft.genre=article&rft.issn=1881-6096&rft.volume=72&rft.issue=5&rft.spage=517 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.